Cardiovascular, renal and metabolic - Novartis
ASCVD is the most common form of cardiovascular disease (CVD) and includes cardiovascular events like heart attacks and strokes 3,4. High levels of low-density lipoprotein cholesterol …
Cardiovascular and metabolic disease research at Novartis
Led by Shaun Coughlin, the team uses every tool at its disposal to better understand the root causes of cardiovascular and metabolic diseases, discover and develop drugs against relevant …
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to ...
Dec 22, 2021 · “Leqvio is a revolutionary approach to lower LDL-C, and creates new possibilities for how healthcare systems can impact cardiovascular disease, a defining public health …
US FDA approves expanded indication for Novartis Leqvio® …
Jul 10, 2023 · Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in …
Heart Failure - Novartis
This characteristic has been described as inflammatory atherosclerosis. At Novartis, we are actively participating in research and clinical development in this highly innovative and novel …
Products | Novartis
Discover the diverse and innovative Novartis Global Product Portfolio and find information about each pharmaceutical treatment.
Novartis bolsters late-stage cardiovascular pipeline with …
Feb 11, 2025 · “Welcoming Anthos Therapeutics strengthens our focus in the cardiovascular space and complements our portfolio of life-changing treatments, comprehensive clinical …
Novartis Pipeline
Discover the Novartis pipeline of over 100 projects in clinical development, many for medicines that could advance treatment standards for patients.
Novartis Entresto® granted expanded indication in chronic heart …
Feb 16, 2021 · In the United States, Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure 1.
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful ...
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio ® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints.